Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)

Summary

• Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen.
• Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia.
• Other younger pipeline assets for orphan diseases would add further value to the deal.

The successful investor is usually an individual who is inherently interested in business problems. - Phillip Fisher (Warren Buffett's one of two mentors)

Author's Note:?This is an abbreviated version of an article originally published in advance?on Jan. 09, inside Integrated BioSci Investing for our members.

In biotech investing, it's an exciting time when you see your stock getting acquired by a larger company. After all, the acquisition price is typically 40% to 80% higher than the current market valuation. More importantly, the deal would allow the drugs to reach the most number of patients and thereby deliver hope in seemingly hopeless situations. The stock that illustrates the aforesaid phenomenon is Albireo Pharma, Inc. (NASDAQ:ALBO). As you will see, Ipsen is set to?acquire Albireo?at a substantial market premium. In this research, I'll feature a fundamental analysis of Albireo while focusing on the deal.

YOU CAN EITHER READ THE 1)?FREE ARTICLE?ON SEEKING ALPHA OR 2)?IN-DEPTH ANALYSIS?INSIDE INTEGRATED BIOSCI INVESTING.